ATE549343T1 - Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol - Google Patents

Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol

Info

Publication number: ATE549343T1
Authority: AT; Austria
Prior art keywords: alpha; dimethylamino; ethylü; meth; bromine
Prior art date: 2005-05-25

Application number

AT06755275T

Other languages

English (en)

Inventor

Frank Porstmann

Stefan Horns

Thomas Bader

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-25

Filing date

2006-05-22

Publication date

2012-03-15

2006-05-22 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE549343T1 publication Critical patent/ATE549343T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)

AT06755275T 2005-05-25 2006-05-22 Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol ATE549343T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05104482		2005-05-25
PCT/EP2006/062502 WO2006125769A1 (en)	2005-05-25	2006-05-22	Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number	Publication Date
ATE549343T1 true ATE549343T1 (de)	2012-03-15

Family

ID=36013279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06755275T ATE549343T1 (de)	2005-05-25	2006-05-22	Verfahren zur herstellung von (alpha s, beta r)-6-brom-alpha-ä2-(dimethylamino)ethylü-2-meth xy- alpha-1-naphthalinyl-beta-phenyl-3- chinolinethanol

Country Status (27)

Country	Link
US (2)	US8039628B2 (de)
EP (1)	EP1888604B1 (de)
JP (1)	JP5410749B2 (de)
KR (2)	KR101534021B1 (de)
CN (1)	CN101180302B (de)
AT (1)	ATE549343T1 (de)
AU (1)	AU2006251208B2 (de)
BR (1)	BRPI0611166B1 (de)
CA (1)	CA2606675C (de)
CY (1)	CY1113383T1 (de)
DK (1)	DK1888604T3 (de)
EA (1)	EA011770B1 (de)
ES (1)	ES2383908T3 (de)
HR (1)	HRP20120429T1 (de)
IL (1)	IL186913A (de)
ME (1)	ME01445B (de)
MX (1)	MX2007014874A (de)
NO (1)	NO341633B1 (de)
NZ (1)	NZ563819A (de)
PL (1)	PL1888604T3 (de)
PT (1)	PT1888604E (de)
RS (1)	RS52316B (de)
SG (1)	SG162724A1 (de)
SI (1)	SI1888604T1 (de)
UA (1)	UA92484C2 (de)
WO (1)	WO2006125769A1 (de)
ZA (1)	ZA200710150B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2668715B2 (ja)	1988-10-21	1997-10-27	住友重機械工業株式会社	コイル集束装置における切断制御法
EP1835115B1 (de)	2006-03-17	2013-05-29	Peter Villiger	Schutzverfahren und Schutzsystem für Wertsachen
RU2486175C2 (ru) *	2011-09-12	2013-06-27	Закрытое Акционерное Общество "Фарм-Синтез"	Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
WO2014014845A1 (en)	2012-07-18	2014-01-23	Vertex Pharmaceuticals Incorporated	Combination therapy comprising\|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-\|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium\|diseases
CN105017147B (zh) *	2014-04-30	2019-02-01	中国医学科学院药物研究所	一种回收和利用Bedaquiline立体化学异构体的方法
CN105085395B (zh) *	2014-05-07	2017-09-26	国药集团国瑞药业有限公司	贝达喹啉的制备方法
CN105085396B (zh) *	2014-05-07	2017-08-08	国药集团国瑞药业有限公司	用于制备贝达喹啉的中间体及其制备方法和应用
CN105198808B (zh) *	2014-05-27	2017-08-25	北京万生药业有限责任公司	一种高效生产贝达喹啉的方法
CN105175329B (zh) *	2014-06-10	2017-09-19	重庆圣华曦药业股份有限公司	一种贝达喹啉消旋体的合成路线及方法
CZ2014708A3 (cs)	2014-10-16	2016-04-27	Zentiva, K.S.	Soli Bedaquilinu
CZ201535A3 (cs)	2015-01-21	2016-08-03	Zentiva, K.S.	Nové možnosti chirální resoluce bedaquilinu
CZ201533A3 (cs)	2015-01-21	2016-08-03	Zentiva, K.S.	Způsob izolace směsi enantiomerů
CZ201534A3 (cs)	2015-01-21	2016-08-03	Zentiva, K.S.	Nové možnosti chirální resoluce bedaquilinu
CN114129526A (zh) *	2015-01-27	2022-03-04	詹森药业有限公司	可分散组合物
CZ2015391A3 (cs)	2015-06-09	2016-12-21	Zentiva, K.S.	Sůl bedaquilinu s kyselinou citronovou
CN107848978B (zh) *	2015-07-24	2021-04-02	浙江海正药业股份有限公司	一种分离贝达喹啉非对映异构体a的方法
EA201891644A1 (ru) *	2016-03-07	2019-04-30	Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк.	Антибактериальные соединения и их применение
CN107602464B (zh) *	2016-07-12	2020-02-18	宜昌人福药业有限责任公司	利用光学拆分制备双芳基喹啉类抗生素的方法
CN106866525B (zh) *	2017-03-24	2019-04-19	福建省微生物研究所	用于合成(1r,2s)-贝达喹啉的手性诱导剂
WO2019012100A1 (en)	2017-07-14	2019-01-17	Janssen Pharmaceutica Nv	EXTENDED ACTION FORMULATIONS
CN109422679B (zh) *	2017-08-30	2021-06-25	武汉武药科技有限公司	一种贝达喹啉的纯化及稳定晶型的制备方法
CN107857727B (zh) *	2017-10-26	2019-10-18	江苏天和制药有限公司	一种（1r，2s）和（1s，2r）-贝达喹啉的制备方法
CN110759885B (zh) *	2018-07-27	2021-10-22	中国医学科学院药物研究所	制备光活依格鲁特的方法
WO2020161743A1 (en)	2019-02-08	2020-08-13	Mylan Laboratories Limited	Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) *	2020-07-01	2021-09-17	동아에스티 주식회사	(1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
WO2022008643A1 (en)	2020-07-09	2022-01-13	Janssen Pharmaceutica Nv	Long-acting formulations
EP4178540A1 (de)	2020-07-09	2023-05-17	JANSSEN Pharmaceutica NV	Formulierungen mit langzeitwirkung
EP4178541A1 (de)	2020-07-09	2023-05-17	JANSSEN Pharmaceutica NV	Formulierungen mit langzeitwirkung
WO2024068693A1 (en)	2022-09-28	2024-04-04	Janssen Pharmaceutica Nv	Long-acting formulations
CN119968203A (zh)	2022-09-28	2025-05-09	詹森药业有限公司	长效配制品
JP7728461B1 (ja)	2023-08-01	2025-08-22	上海交通大学	低温で連続フローによりベダキリンを調製する方法及びこの方法により調製された製品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2111138A1 (en) *	1993-01-15	1994-07-16	Thierry Godel	Octahydrophenanthrene derivatives
US5319084A (en) *	1993-08-16	1994-06-07	Research Triangle Institute	Hexahydroindenopyridine compounds having antispermatogenic activity
PT1527050E (pt) *	2002-07-25	2010-06-22	Janssen Pharmaceutica Nv	Derivados de quinolina e sua utilização como inibidores de micobactérias
WO2004060889A1 (en)	2003-01-07	2004-07-22	Glaxo Group Limited	5-thiazole substituted 2-pyrrolidine-carboxylic acids

2006
- 2006-05-22 EP EP06755275A patent/EP1888604B1/de not_active Expired - Lifetime
- 2006-05-22 SG SG201003636-6A patent/SG162724A1/en unknown
- 2006-05-22 ES ES06755275T patent/ES2383908T3/es not_active Expired - Lifetime
- 2006-05-22 AU AU2006251208A patent/AU2006251208B2/en not_active Ceased
- 2006-05-22 BR BRPI0611166-1A patent/BRPI0611166B1/pt not_active IP Right Cessation
- 2006-05-22 PT PT06755275T patent/PT1888604E/pt unknown
- 2006-05-22 US US11/915,204 patent/US8039628B2/en active Active
- 2006-05-22 SI SI200631344T patent/SI1888604T1/sl unknown
- 2006-05-22 CN CN2006800174755A patent/CN101180302B/zh not_active Expired - Lifetime
- 2006-05-22 NZ NZ563819A patent/NZ563819A/en not_active IP Right Cessation
- 2006-05-22 CA CA2606675A patent/CA2606675C/en not_active Expired - Lifetime
- 2006-05-22 AT AT06755275T patent/ATE549343T1/de active
- 2006-05-22 KR KR1020077028419A patent/KR101534021B1/ko not_active Expired - Lifetime
- 2006-05-22 KR KR1020147036245A patent/KR101712835B1/ko not_active Expired - Lifetime
- 2006-05-22 WO PCT/EP2006/062502 patent/WO2006125769A1/en not_active Ceased
- 2006-05-22 MX MX2007014874A patent/MX2007014874A/es active IP Right Grant
- 2006-05-22 JP JP2008512822A patent/JP5410749B2/ja not_active Expired - Lifetime
- 2006-05-22 UA UAA200711767A patent/UA92484C2/ru unknown
- 2006-05-22 ME MEP-2012-64A patent/ME01445B/me unknown
- 2006-05-22 EA EA200702611A patent/EA011770B1/ru unknown
- 2006-05-22 HR HRP20120429TT patent/HRP20120429T1/hr unknown
- 2006-05-22 DK DK06755275.2T patent/DK1888604T3/da active
- 2006-05-22 PL PL06755275T patent/PL1888604T3/pl unknown
- 2006-05-22 RS RS20120212A patent/RS52316B/sr unknown
2007
- 2007-10-25 IL IL186913A patent/IL186913A/en active IP Right Grant
- 2007-11-26 ZA ZA2007/10150A patent/ZA200710150B/en unknown
- 2007-12-19 NO NO20076542A patent/NO341633B1/no unknown
2011
- 2011-09-06 US US13/225,647 patent/US8350040B2/en active Active
2012
- 2012-06-12 CY CY20121100534T patent/CY1113383T1/el unknown

Also Published As

Publication number	Publication date
EA200702611A1 (ru)	2008-04-28
HK1118061A1 (en)	2009-01-30
US20110319623A1 (en)	2011-12-29
ZA200710150B (en)	2012-06-27
PT1888604E (pt)	2012-05-28
ME01445B (me)	2013-12-20
AU2006251208A1 (en)	2006-11-30
IL186913A (en)	2013-12-31
HRP20120429T1 (hr)	2012-06-30
RS52316B (sr)	2012-12-31
EA011770B1 (ru)	2009-06-30
KR20080010453A (ko)	2008-01-30
SG162724A1 (en)	2010-07-29
BRPI0611166B1 (pt)	2022-01-25
PL1888604T3 (pl)	2012-08-31
CY1113383T1 (el)	2016-06-22
UA92484C2 (en)	2010-11-10
KR101534021B1 (ko)	2015-07-06
SI1888604T1 (sl)	2012-08-31
ES2383908T3 (es)	2012-06-27
IL186913A0 (en)	2008-02-09
NO20076542L (no)	2007-12-19
NO341633B1 (no)	2017-12-11
KR20150008196A (ko)	2015-01-21
KR101712835B1 (ko)	2017-03-07
CA2606675A1 (en)	2006-11-30
BRPI0611166A2 (pt)	2010-08-17
AU2006251208B2 (en)	2012-11-29
US20080200683A1 (en)	2008-08-21
CA2606675C (en)	2013-02-19
EP1888604B1 (de)	2012-03-14
NZ563819A (en)	2011-01-28
WO2006125769A1 (en)	2006-11-30
CN101180302B (zh)	2013-06-19
DK1888604T3 (da)	2012-06-18
CN101180302A (zh)	2008-05-14
JP2008545675A (ja)	2008-12-18
MX2007014874A (es)	2008-02-15
EP1888604A1 (de)	2008-02-20
US8350040B2 (en)	2013-01-08
US8039628B2 (en)	2011-10-18
JP5410749B2 (ja)	2014-02-05

Publication	Publication Date	Title
CY1113383T1 (el)	2016-06-22	Μεθοδος για την παρασκευη (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
ATE486844T1 (de)	2010-11-15	Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien
DE602004014910D1 (de)	2008-08-21	Verfahren zur herstellung von derivaten chiraler beta-aminosäuren durch assymetrische hydrierung
ATE430480T1 (de)	2009-05-15	Verfahren zur herstellung von nährmittelzusammensetzungen
ATE425136T1 (de)	2009-03-15	Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE443038T1 (de)	2009-10-15	Verfahren zur herstellung von cinacalcet hydrochlorid
ATE542803T1 (de)	2012-02-15	Verfahren zur herstellung von dihydrochinazolinen
ATE544754T1 (de)	2012-02-15	Verfahren zur herstellung von ivabradinhydrochlorid
DE602004030239D1 (de)	2011-01-05	Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
DE602004029247D1 (de)	2010-11-04	Verfahren zur herstellung eines olefinoxids
ATE539054T1 (de)	2012-01-15	Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
ATE444950T1 (de)	2009-10-15	Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE486857T1 (de)	2010-11-15	Verfahren zur herstellung von telmisartan
DE502004005626D1 (de)	2008-01-10	Verfahren zur herstellung von organoacylphosphiten
DE602006021411D1 (de)	2011-06-01	Verfahren zur herstellung von optional 2-substituierten 1,6-dihydro-6-oxo-4-pyrimidincarboxylsäuren
GT200400248A (es)	2005-09-14	Proceso para la preparacion de inhibidores de tubulina
ATE514702T1 (de)	2011-07-15	Verfahren zur herstellung von clopidogrel und dabei verwendete zwischenprodukte
ATE370950T1 (de)	2007-09-15	Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
ATE388949T1 (de)	2008-03-15	Verfahren zur herstellung von z-flupentixol
ATE466010T1 (de)	2010-05-15	Verfahren zur herstellung von candesartan
ATE515502T1 (de)	2011-07-15	Verfahren zur herstellung von tetranorlabdanderivaten
ATE549315T1 (de)	2012-03-15	Verfahren zur herstellung von kristallinem perindopril
DE602004030091D1 (de)	2010-12-30	Verfahren zur reduktiven deshalogenierung
ATE349418T1 (de)	2007-01-15	Verfahren zur herstellung von nateglinidin der b- form
DE50203388D1 (de)	2005-07-14	Verbessertes verfahren zur herstellung von bisphosphiten